Oversight of Laboratory Developed Tests; Public Meeting; Change of Meeting Location, 39954 [2010-16974]

Download as PDF 39954 Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Notices Justification) is not double spaced: Deduction of 5 points. Margins less than 1⁄2 inch: Deduction of 3 points. Font is not at least 12-point size or Times New Roman: Deduction of 2 points.’’ Please replace the deleted language under Section IV.2. Content and Form of Application Submission with the following: ‘‘Applications that do not adhere to the prescribed format will be converted to conform with the prescribed format. Should the conversion result in a document which exceeds 90 pages, all pages exceeding the 90page limit will be removed and will not be considered in the reviewing process.’’ All information in this modification is accurate and replaces information specified in the June 2, 2010 Funding Opportunity Announcement. Announcement Availability: To access this Program Announcement please go to the ACF Grant Opportunities webpage at https://www.acf.hhs.gov/ grants/ or to https:// www.Grants.gov. FOR FURTHER INFORMATION CONTACT: Victoria Marquez at 202–205–4866 and Victoria.Marquez@acf.hhs.gov. Dated: July 1, 2010. Bryan Samuels, Commissioner, Administration on Children, Youth and Families. [FR Doc. 2010–17069 Filed 7–12–10; 8:45 am] BILLING CODE 4182–04–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2010–N–0274] Food and Drug Administration, HHS. jlentini on DSKJ8SOYB1PROD with NOTICES ACTION: I. Background In the Federal Register of June 17, 2010 (75 FR 34463), FDA published a notice announcing a public meeting that is intended to create a forum for interested stakeholders to discuss the agency’s oversight of laboratory developed tests. FDA announced in the notice that it is seeking input and requesting comments on this topic. The June 17, 2010, notice invited individuals interested in presenting to register by July 12, 2010. Registration to present at the public meeting is closed. All others are welcome to attend on a first-come, first-served basis. Because of greater than anticipated response for attending the public meeting, FDA is announcing in this notice a new location for the public meeting. II. New Location for the Public Workshop The new location will be The Marriott Inn & Conference Center, University of Maryland University College (see ADDRESSES). Directions and information on parking, accommodations, and transportation options can be found at: https://www.marriott.com/hotels/travel/ wasum-the-marriott-inn-andconference-center-university-ofmaryland-university-college/. Dated: July 7, 2010. Nancy Stade, Acting Associate Director for Regulations and Policy, Center for Devices and Radiological Health. Oversight of Laboratory Developed Tests; Public Meeting; Change of Meeting Location AGENCY: FOR FURTHER INFORMATION CONTACT: Katherine Serrano, Center for Devices and Radiological Health, Food and Drug Administration 10903 New Hampshire Ave., Bldg. 66., rm 5613, Silver Spring, MD 20993–0002, 301–796–6652, e-mail: Katherine.serrano@fda.hhs.gov. SUPPLEMENTARY INFORMATION: [FR Doc. 2010–16974 Filed 7–12–10; 8:45 am] BILLING CODE 4160–01–S Notice. SUMMARY: The Food and Drug Administration (FDA) is announcing a change in location for the upcoming public meeting entitled ‘‘Oversight of Laboratory Developed Tests.’’ A new address is given for those attending the public meeting. DATES: The public meeting will be held on July 19 and 20, 2010, from 8 a.m. to 5 p.m. each day. ADDRESES: The public meeting will be held at The Marriott Inn & Conference Center, University of Maryland University College, 3501 University Blvd. E, Hyattsville, MD 20783. VerDate Mar<15>2010 16:44 Jul 12, 2010 Jkt 220001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Director, National Institutes of Health; Notice of a Conference Call of the NIH Scientific Management Review Board Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a conference call meeting of the Scientific Management Review Board. PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 The NIH Reform Act of 2006 (Pub. L. 109–482) provides organizational authorities to HHS and NIH officials to: (1) Establish or abolish national research institutes; (2) reorganize the offices within the Office of the Director, NIH including adding, removing, or transferring the functions of such offices or establishing or terminating such offices; and (3) reorganize, divisions, centers, or other administrative units within an NIH national research institute or national center including adding, removing, or transferring the functions of such units, or establishing or terminating such units. The purpose of the Scientific Management Review Board (also referred to as SMRB or Board) is to advise appropriate HHS and NIH officials on the use of these organizational authorities and identify the reasons underlying the recommendations. Name of Committee: Scientific Management Review Board. Date: July 26, 2010. Time: 10:30 a.m. to 12 p.m. (EST) Agenda: Presentation will include an overview and discussion of a new charge to the SMRB, which entails considering the attributes and functions of a translational medicine program optimized to accelerate therapeutics development. Time will be allotted on the agenda for public comment. To sign up for public comment, please submit your name and affiliation to the contact person listed below by July 25, 2010. Sign up will be restricted to one sign up per email. In the event that time does not allow for all those interested to present oral comments, anyone may file written comments using the contact person address below. Dial-In Information: The toll-free number to participate in this call is 1–800–779–1545. Indicate to the conference operator that your participant pass code is ‘‘NIH’’. Contact Person: Dr. Lyric Jorgenson, Office of Science Policy, Office of the Director, NIH, National Institutes of Health, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892, (301) 496–6837, smrb@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. The draft agenda, meeting materials, dialin information, and other information about the SMRB, will be available at https:// smrb.od.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93,936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate E:\FR\FM\13JYN1.SGM 13JYN1

Agencies

[Federal Register Volume 75, Number 133 (Tuesday, July 13, 2010)]
[Notices]
[Page 39954]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-16974]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0274]


Oversight of Laboratory Developed Tests; Public Meeting; Change 
of Meeting Location

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing a change 
in location for the upcoming public meeting entitled ``Oversight of 
Laboratory Developed Tests.'' A new address is given for those 
attending the public meeting.

DATES: The public meeting will be held on July 19 and 20, 2010, from 8 
a.m. to 5 p.m. each day.

ADDRESES: The public meeting will be held at The Marriott Inn & 
Conference Center, University of Maryland University College, 3501 
University Blvd. E, Hyattsville, MD 20783.

FOR FURTHER INFORMATION CONTACT: Katherine Serrano, Center for Devices 
and Radiological Health, Food and Drug Administration 10903 New 
Hampshire Ave., Bldg. 66., rm 5613, Silver Spring, MD 20993-0002, 301-
796-6652, e-mail: Katherine.serrano@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background

    In the Federal Register of June 17, 2010 (75 FR 34463), FDA 
published a notice announcing a public meeting that is intended to 
create a forum for interested stakeholders to discuss the agency's 
oversight of laboratory developed tests. FDA announced in the notice 
that it is seeking input and requesting comments on this topic. The 
June 17, 2010, notice invited individuals interested in presenting to 
register by July 12, 2010. Registration to present at the public 
meeting is closed. All others are welcome to attend on a first-come, 
first-served basis.
    Because of greater than anticipated response for attending the 
public meeting, FDA is announcing in this notice a new location for the 
public meeting.

II. New Location for the Public Workshop

    The new location will be The Marriott Inn & Conference Center, 
University of Maryland University College (see ADDRESSES). Directions 
and information on parking, accommodations, and transportation options 
can be found at: https://www.marriott.com/hotels/travel/wasum-the-marriott-inn-and-conference-center-university-of-maryland-university-college/.

    Dated: July 7, 2010.
Nancy Stade,
Acting Associate Director for Regulations and Policy, Center for 
Devices and Radiological Health.
[FR Doc. 2010-16974 Filed 7-12-10; 8:45 am]
BILLING CODE 4160-01-S

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.